Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07667673 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multimodality RV Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 PAH

Study acronym: MIRROR-PAH
StatusActive, Not Recruiting
PhaseNot specified
Started2026-05-11
View on ClinicalTrials.gov ↗

Amendment history

2026-09-19
notable
Enrollment closed, study ongoing
The MIRROR-PAH is a single-center, prospective, observational cohort study evaluating the incremental value of multimodality imaging-derived right ventricular characteristics for risk stratification in patients with Group 1 pulmonary arterial hypertension (PAH). The study aims to determine whether incorporation of echocardiographic and cardiac magnetic resonance (CMR)-derived right ventricular parameters into established non-invasive risk assessment models results in risk reclassification and improves identification of patients at risk for short-term clinical worsening. Adult patients with established Group 1 PAH undergoing routine follow-up and with available right heart catheterization (RHC) and CMR data will be consecutively enrolled. Clinical, laboratory, echocardiographic, and follow-up data will be prospectively collected over a 6-month period. Associations between multimodality imaging findings, invasive hemodynamic measurements, risk classification, and short-term clinical outcomes will be evaluated.
Trial Details
NCT Number NCT07667673
Lead Sponsor Istanbul University - Cerrahpasa
Conditions Pulmonary Hypertension, Pulmonary Arterial Hypertension, Right Ventricular Function
Enrollment 50 participants
Start Date 2026-05-11
Primary Completion 2027-02 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-09-18